Lipigon Q4 2024: Rights issue funds 2025 - Redeye
Bildkälla: Stockfoto

Lipigon Q4 2024: Rights issue funds 2025 - Redeye

Redeye comments on Lipigons third quarter report, including positive phase I results for Leaderna, clinical data from Marea and the rights issue.

Redeye comments on Lipigons third quarter report, including positive phase I results for Leaderna, clinical data from Marea and the rights issue.
Börsvärldens nyhetsbrev
ANNONSER